Table 1.
Summary of samples used in this study.
| Virus | Hours post-infection | Virus strain | Cell | Accession number |
|---|---|---|---|---|
| DENV-2 | 72 | TSV01 | A549 | PRJNA552644 |
| Flu-A | – | PR8 | A549 | PRJNA495858 |
| Flu-B | – | B/Yamagata | A549 | PRJNA605905 |
| ZIKV | 48 | FSS13025 | hiNPCs | PRJNA551246 |
| 48 | PE243V | hiNPCs | ||
| HCV | 12 | – | Huh7 | PRJNA559203 |
| 36 | – | Huh7 | ||
| 60 | – | Huh7 | ||
| WNV | – | – | A549 | PRJNA577579 |
| CCHFV | 24 | – | Huh7 | PRJNA549926 |
| 72 | – | Huh7 | ||
| 24 | – | HepG2 | ||
| 72 | – | HepG2 | ||
| EBV | – | Akata | differentiated NOKs | PRJNA555053 |
| – | Akata | undifferentiated NOKs | ||
| MV | – | – | MSC (5H) | PRJNA545099 |
| – | – | MSC (hTERT) | ||
| RSV | 24 | A2 | A549 | PRJNA615032 |
| SARS-CoV-2 | 24 | USA-WA1/2020 | A549 | PRJNA615032 |
| 24 | USA-WA1/2020 | NHBE | ||
| RHV | 6 | – | Calu3 | PRJNA609228 |
| 24 | – | Calu3 |